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ABSTRACT
Pregabalin is a first-line treatment in all major
international guidelines on the management of
painful diabetic neuropathy (pDPN). Treatment
with pregabalin leads to a clinically meaningful
improvement in pain scores, offers consistent
relief of pain and has an acceptable tolerance
level. Despite its efficacy in relieving neuro-
pathic pain, more robust methods and com-
prehensive studies are required to evaluate its
effects in relation to co-morbid anxiety and
sleep interference in pDPN. The sustained
benefits of modulating pain have prompted
further exploration of other potential target
sites and the development of alternative
GABAergic agents such as mirogabalin. This
review evaluates the role of pregabalin in the
management of pDPN as well as its potential
adverse effects, such as somnolence and dizzi-
ness, which can lead to withdrawal in * 30% of
long-term use. Recent concern about misuse
and an increase in deaths linked to its use has
led to demands for reclassification of pregabalin
as a class C controlled substance in the UK. We
believe these demands need to be tempered in
relation to the difficulties it would create for
repeat prescriptions for the many millions of
patients with pDPN for whom pregabalin pro-
vides benefit.Enhanced Digital Features To view enhanced digital
features for this article go to: https://doi.org/10.6084/
m9.figshare.7398635.
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PLAIN LANGUAGE SUMMARY
Diabetic peripheral neuropathy (DPN) is a dis-
ease of the nerves in the hands and feet and is a
common complication of both type 1 and type
2 diabetes. The symptoms of DPN include loss
of sensation, weakness and pain. Around
30–40% of people with diabetes have DPN, and
its burden will rise with the exponential
increase of diabetes worldwide. pDPN is a
debilitating complication not only affecting the
patient’s quality of life, but also has a major
impact on the healthcare services. Pregabalin is
a first-line therapy in pDPN that offers adequate
pain relief and is well tolerated. Moreover, it is
also effective in treating the co-morbidities of
pDPN, which include anxiety and sleep inter-
ference. Nonetheless, further studies are
required to investigate the effectiveness and
underlying mechanisms of the benefits of pre-
gabalin on anxiety and sleep disorders and to
determine the type of patient that benefits most
from this therapy. We also provide an overview
of the mechanisms by which GABAergic drugs
work in pDPN and consider new emerging
therapies in this area.
INTRODUCTION
Pregabalin was approved for the management of
neuropathic pain in 2004 in Europe and the US.
First synthesised in 1990 [1], pregabalin (3-iso-
butyl gamma amino butyric acid gamma-ana-
logue) [2] is a GABAergic drug primarily used in
the treatment of neuropathic pain and is
approved for use in over 120 countries. Its use as
an adjuvant anti-epileptic is generally limited
[3], although it is approved for use in partial
seizures [4]. In clinical practice it can be used to
treat generalised anxiety disorder because of its
anxiolytic properties [4], but is primarily pre-
scribed for painful diabetic neuropathy (pDPN),
post-herpetic neuralgia and radicular pain as
well as fibromyalgia [5, 6]. Pregabalin and
gabapentin are considered first-line treatment
in the majority of international clinical guide-
lines for pDPN and form a key part of its man-
agement. Five professional bodies have
produced expert guidance on the management
of pDPN [7–11] and pregabalin is recommended
as first-line therapy in all five guidelines, whilst
duloxetine is recommended as first line in four
of the guidelines (except the American Acad-
emy of Neurology) [7–11]. The latter is driven
by only one duloxetine trial, being graded as
class 1 evidence, because completion rates of
other trials are\ 80% [10].
Pregabalin is structurally related to the inhi-
bitory neurotransmitter GABA; however, its
mechanism of action is distinct from GABAergic
modulation and is yet to be fully elucidated.
Pain relief usually occurs within 1 week of ini-
tiating therapy and is thought to be mediated
via high-affinity binding to the alpha2-delta
subunit (a2d) of voltage-gated calcium channels
at the presynaptic terminals [12]. This results in
modulation of the release of excitatory neuro-
transmitters such as glutamate [12] through the
glutamate synthesising enzyme, branched-
chain amino acid transaminase [13, 14].
Pregabalin’s mechanism of action is similar
to that of gabapentin; however, it has 2–4 times
more potency and thus a lower dosing strategy
is required [15]. Typically starting doses range
from 75 to 150 mg per day for neuropathic pain,
with relatively quick up-titration over several
weeks to maximal tolerated doses (600 mg/day)
due to the more linear pharmacokinetics com-
pared with gabapentin [15]. It has high
bioavailability (C 90% rapidly absorbed)
[16, 17] with a half-life of approximately 9 h
[18]. Very common adverse effects ([10% of
patients) include dizziness, somnolence and
headache [17]. Pregabalin demonstrates quick
absorption, reducing the probability of drug-
drug interactions as it is not bound to plasma
proteins and does not undergo first-pass meta-
bolism in the liver [4, 19]. Although pregabalin
poses low risk for addiction and drug depen-
dence at therapeutic doses [20], recent statistics
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in England and Wales showed a [ 20-fold
increase in the number of deaths linked to
pregabalin—4 to 111 deaths from 2012 to 2016,
whilst for gabapentin—8 to 59 deaths during
the same period [21]. Rapid rise in mortality is
associated with individuals with previous his-
tory of recreational polydrug misuse, or misuse
in combination with opioids, as some report
self-administration of dosages in excess (e.g., up
to 10–20 times) of clinically advisable dosages
[22]. Consequently, this led to guidance from
Public Health England and the NHS on safe
prescribing of both pregabalin and gabapentin
[23]. However, in December 2017 NHS England
launched a consultation to seek views on whe-
ther to schedule pregabalin and gabapentin as
Controlled drugs in the UK. A similar consul-
tation is underway with the WHO and a deci-
sion is expected in early 2019. Due to their ‘‘risk
of addiction, potential illegal diversion and
medicinal misuse’’ by a minority, the reclassifi-
cation of these drugs will have major repercus-
sions on the many millions of people suffering
from neuropathic pain, as it will restrict pre-
scribing and also prevent them from acquiring
the drug on a repeat prescription.
METHODS
A comprehensive literature review was under-
taken, incorporating article searches in elec-
tronic databases (EMBASE, PubMed, OVID) and
reference lists of relevant articles with the
authors’ expertise in pDPN. The key following
keywords were utilised; ‘painful diabetic neu-
ropathy’, ‘diabetic neuropathy’, ‘sleep interfer-
ence’, ‘anxiety’ and ‘depression’ in combination
with ‘pregabalin’. This article is based on pre-
viously conducted studies and does not contain
any studies with human participants or animals
performed by any of the authors.
pDPN Prevalence and the Need
for Therapy
Diabetes has reached epidemic proportions
worldwide, with current International Diabetes
Federation (IDF) estimates suggesting a preva-
lence of 425 million people worldwide in 2017,
rising to 628 million by 2045 [24]. Epidemio-
logical studies show DPN has a prevalence of
30–40% in patients with diabetes [25–27],
which increases with the duration of disease,
rising to approximately 50% in those patients
who have had the disease for[ 20 years [26].
The symptoms can be varied with patients pre-
senting with paraesthesia, weakness and pain,
which may by burning, tingling or shooting in
nature. Pain can have a negative impact on
patient’s quality of life and sleep. There are
currently no FDA approved therapies to pre-
vent, slow or arrest DPN, and management
involves achieving good glycaemic control and
targeting modifiable vascular risk factors to halt
the progression alongside symptomatic treat-
ment. The management of pDPN is key to
improving quality of life and general well-be-
ing; however, therapeutic options in pDPN are
often limited by side effects. Pregabalin has a
higher potency than gabapentin thus requiring
lower doses, recommended dose of up to 600
mg/day in management of pDPN and a superior
adverse effect profile [28]. It is the only agent in
the gabapentanoid class with a current label for
the treatment of pDPN [29]. Indeed, pregabalin
is the only agent other than duloxetine and
tapentadol to have FDA approval for the treat-
ment of neuropathic pain [29].
Pharmacodynamics
GABA is a major inhibitory neurotransmitter in
the central nervous system exerting inhibitory
control on the spinal dorsal horn [30]. It is
released by inhibitory descending fibres and
interneurons and binds to both the GABAA (via
ionotropic) and GABAB (via metabotropic)
receptors depressing neuronal excitation and
reducing glutamate release from primary affer-
ent fibres onto dorsal horn neurones [31].
Modulation of excitatory neurotransmitters
such as glutamate [12] through the glutamate
synthesising enzyme, branched-chain amino
acid transaminase, is thought to play a possible
role in pain in pDPN [13, 14]. Loss of the
GABAergic inhibitory process has been identi-
fied as an underlying mechanism of inflamma-
tory and neuropathic pain [32]; however, the
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exact mechanism remains unclear. A reduction
in the expression of the potassium chloride
transporter (KCC2) with primary sensory neu-
rones exhibiting a higher intracellular chloride
level has also been proposed as a possible con-
tributory mechanism [33].
Despite being developed as a mimetic of
GABA, pregabalin is not believed to produce any
of its therapeutic effects directly via the GABA
receptor. Ahighaffinity to thea2-d subunit found
in a number of voltage-gated calcium channels
(VGCC) is considered its primary mechanism of
action [34]. Indeed, genetic knock-out of a2-d in
animal models entirely negates the analgesic
effects of pregabalin [35, 36].
Absorption Distribution, Metabolism,
Excretion and Interactions
Pregabalin’s bioavailability is over 90% and is
dose independent [37]. Food does not affect
pregabalin’s overall exposure; however, it can
reduce the rate of absorption with the content
of the food having little effect on this [38, 39].
Maximal serum concentrations appear
0.7–1.3 h post-dose [39] with the serum half-life
ranging from 4.6 to 6.8 h [39]. Over 90% of its
excretion is via the kidney [40]. There are very
few drug-drug interactions reported with pre-
gabalin [37], which may be in part because it
has no significant effects on the CYP450 family
[19]. As such, the only major clinical factor
relevant to dosing is renal function. The maxi-
mum dose of 600 mg/day should only be used
in patients with a creatinine clearance
(CrCl)[ 60 ml/min. In patients whose CrCL is
15–30 ml/min, the maximum dose should be
reduced 150 mg in 1–2 divided doses and when
CrCL is\15 ml/min this needs to be reduced
further to a maximum of 75 mg once daily. The
indications, dosing, renal dosing, and minor
and major side effects for pregabalin, gaba-
pentin and the emerging GABAergic therapy,
mirogabalin, are presented in Tables 1 and 2.
Adverse Effects
The frequently reported side effects of prega-
balin include somnolence, dizziness, peripheral
oedema and weight gain, which are usually
mild to moderate [39, 41, 42]. These effects are
thought to be related to the drug’s effects on
neurotransmitter release and calcium currents.
Pregabalin may cause adverse events on cogni-
tion and coordination [43]. In addition, treat-
ment is associated with weight gain, which is in
part dependent on the total drug dose, thus
raising an issue that needs to be considered in
treating patients with type 2 diabetes. There is a
theoretical risk of worsening metabolic control
with the associated weight gain from gabapen-
tanoids; a pooled analysis of data from 11
double-blind randomised controlled trials (RCT)
of pregabalin (150–600 mg/day) vs. placebo
showed no clinically meaningful effects of pre-
gabalin on glycaemic or lipid profiles in patients
with pDPN, whilst data on weight were not
presented [44]. The effects on weight should be
considered when starting pregabalin as part of a
personalised treatment approach.
Efficacy of Pregabalin in pDPN: Evidence
from RCTs
RCTs of pregabalin in pDPN, including NCT
number, primary outcome measures and study
population details, are summarised in Table 3.
The efficacy of pregabalin in pDPN is proven
through numerous RCTs (Table 3) and system-
atic reviews. Pregabalin is the first drug to
receive an approved labelling from the Food
and Drug Association (FDA) for the treatment of
pDPN and post-herpetic neuralgia [45]. It is the
recommended first-line treatment in all five
major international clinical guidelines for
pDPN [7–11]. In an early RCT of pregabalin in
pDPN in 2004, Rosenstock et al. showed signif-
icant improvement in the mean pain scores,
sleep interference, mood disturbance and ten-
sion anxiety over 8 weeks on pregabalin
300 mg/day (n = 146) [46]. Pregabalin was well
tolerated despite the mild-to-moderate adverse
events of increased dizziness and somnolence
[46]. A shorter 5-week double blind multi-centre
RCT (n = 338) randomised patients to receive
150 mg/day, 300 mg/day or 600 mg/day of pre-
gabalin or placebo [47]. Participants in the
300 mg/day and 600 mg/day subgroups showed
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Table 1 Pregabalin, gabapentin doses, titration, side effects and major side effects
Indications of use
other than pDPN
Dose in pDPN Renal
impairment
Commonly
reported side
effects
Major side effects
Pregabalin
(Lyrica)
General neuropathic
pain, ﬁbromyalgia,
epilepsy, post-
operative pain,
generalised anxiety
disorder, post-
herpetic neuralgia
Initial: 75 mg
BID
Titration: 150 mg
BID within 1 week
based on efﬁcacy
and tolerability
Maximum dose:
600 mg a day in
patients with CrCl
of C 60 ml/min
CrCl\ 15 ml/
min: Initial
dose: 25 mg
OD
Maintenance:
25–75 mg OD
CrCl 15–30 ml/
min: initial dose:
25–50 mg in
1–2 divided
doses
Maintenance:
25–150 mg/day
in 1–2 divided
doses
CrCl 30–60 ml/
min: initial dose:
75 mg/day in 2
or 3 divided
doses
Maintenance:
75–300 mg/day
in 2–3 divided
doses
Drowsiness,
dizziness,
fatigue, ataxia,
headache,
blurred vision,
peripheral
oedema,
tremor, weight
gain
Confusion, visual
disturbance,
abnormal gait,
abnormality in
thinking, amnesia,
vertigo
Gabapentin
(off-label)
(Neurontin,
Horizant,
Gralise)
General neuropathic
pain, ﬁbromyalgia,
epilepsy, restless
legs syndrome, pain
associated with
Guillain-Barre´
syndrome,
phantom limb pain
Neuropathic pain:
initial dose:
300 mg day 1,
300 mg BD day 2,
300 mg TDS day 3
Therapeutic dose:
1800–3600 mg/day
in 3 divided doses in
patients with CrCl
C 60 ml/min
Maximum dose:
3600 mg/day in 3
divided doses
Mood or
behaviour
changes,
anxiety, panic
attacks, trouble
sleeping,
impulsive,
irritable,
agitated,
oedema
Increased seizures,
severe weakness or
tiredness, ataxia,
upper GI pain,
severe tingling or
numbness, rapid
eye movement,
little or no
urination, oedema,
depression or
suicidal thoughts
OD once daily, BID two times daily, TDS three times daily
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an improvement in mean pain score, sleep
interference score, patient global impression of
change, short-form (SF) McGill Questionnaire
and multiple domains for the SF-36 Health
Survey [47]. There was a[50% reduction in
pain compared with baseline in 45% on
300 mg/day and 48% on 600 mg/day of prega-
balin compared with 18% on placebo [47]. In
both studies, improvement in pain and sleep
began at 1 week and continued throughout the
titration and maintenance phase.
In a 6-week RCT (n = 246) of patients ran-
domised to 150 mg/day or 600 mg/day or pla-
cebo [48], 600 mg/day of pregabalin led to a
reduction in the mean pain score to 4.3 (vs. 5.6
for placebo, P = 0.002) [49]. There was an
increase in the proportion of participants who
had a C 50% reduction of the mean pain score
from baseline (39% vs. 15% for placebo,
P = 0.002). This trial did not show efficacy of
150 mg/day of pregabalin compared with pla-
cebo. Furthermore, a multi-centre trial (n = 338)
reported significant reduction in the mean pain
score in two different titration regimes of pre-
gabalin with both final doses being 600 mg [49].
More recently, Toole et al. evaluated 395
patients over 12 weeks randomised to prega-
balin 150 mg, 300 mg or 600 mg or placebo
[28]. Forty-six per cent of patients on
600 mg/day report a[ 50% improvement in
mean pain score from baseline (vs. 30% in
placebo, P = 0.036) [28]. Pregabalin 600 mg/day
had superior efficacy; however, there was no
significant benefit with 150 mg/day or
300 mg/day subgroups compared with placebo
[28]. The authors suggest this finding may be a
result of the larger placebo response in one of
the countries that participated who represented
42% of the patients [28]. The number needed to
treat (NNT) was 6.3, whilst the number needed
to harm (NNH) (discontinuation because of
adverse events) was 10.3 for pregabalin
600 mg/day [28]. Pooled data from a recent
meta-analysis supported previous data showing
that pregabalin was superior to placebo for
improving mean pain scores [50]. A 50% pain
reduction was greater with pregabalin than
placebo. Three studies compared pregabalin at
lower doses versus higher doses (600 mg/day)
and the withdrawal rate was higher with pre-
gabalin 600 mg/day [51]. Overall, pregabalin
was well tolerated despite an increased risk of
adverse events which limit dose titration.
Gilron et al. evaluated pregabalin across a
range of neuropathic pain conditions, not lim-
ited to pDPN [52]. This RCT (n = 256) allowed
for the assessment of concomitant, potentially
confounding analgesics with stable dosing, thus
reducing bias [52]. Flexible-dose pregabalin was
prescribed for 4 weeks and some participants
continued treatment for a further 5 weeks [52].
Modest levels of analgesia were observed at all
Table 2 Emerging GABAergic therapies
Indication Dose Renal
impairment
Commonly reported side
effects
Major side
effects
Mirogabalin Peripheral neuropathy
ﬁbromyalgia, post-herpetic
neuralgia (marketing
application submitted Feb.
2018; approval/launch
planned for 2019) [117]
Initial dose:
15 mg OD
Maintenance
dose: 15 mg
OD or BD
Maximum
dose:
30 mg/day
CrCl
15–29 ml/
min:
7.5 mg
OD
CrCl
30–59 ml/
min:
7.5 mg BD
[118]
Somnolence, dizziness,
headache, balance
disorder, vomiting,
peripheral oedema,
fatigue, constipation,
decreased appetite
Headache,
cardiac
conduction
abnormality,
arrhythmia
OD once daily, BID two times daily
40 Diabetes Ther (2019) 10:35–56
Table 3 Randomised controlled trials of pregabalin in patients with pDPN
Publication(s) Study title NCT ID No. patients randomised Primary outcome
measures/results
Country (no. of study
centres)
Mu et al.
[119]
An 11-week randomised,
double-blind, multi-
centre, placebo-
controlled study to
evaluate the efﬁcacy,
safety and tolerability of
pregabalin (300
mg/day) using a ﬁxed
dosing schedule in
treatment of subjects
with pain associated
with diabetic peripheral
neuropathy
NCT0133
2149
620 participants;
pregabalin, n = 313
placebo, n = 307
Baseline MPS, change
from baseline in MPS at
end point (day 63/week
9)
Improvement in MPS with
pregabalin vs. placebo
was not signiﬁcant
(P = 0.0559). Pregabalin
signiﬁcantly improved
weekly MPS
(P = 0.0164)
and C 50% responders
at end point
(P = 0.0384)
Multi-centre: Chinese
population
30 study centres in
China
Huffman et al.
[120]
A phase 3B multi-centre,
double-blind,
randomised, placebo-
controlled cross-over
efﬁcacy and safety study
of pregabalin in the
treatment of patients
with painful diabetic
peripheral neuropathy
and pain on walking
NCT0147
4772
203 patients in 2-period
crossover study
(pregabalin, n = 198;
placebo, n = 186)
No statistically signiﬁcant
treatment difference for
pregabalin vs. placebo,
mean DPN pain
(P = 0.0656) and mean
DPN pain on walking
(P = 0.412)
Multi-centre, 30 study
centres in US, Czech
Republic, South
Africa and Sweden
Raskin et al.
[121]
A study of pregabalin in
the treatment of subjects
with painful diabetic
peripheral neuropathy
with background
treatment of NSAID for
other pain conditions
NCT0145
5415
154 patients pregabalin to
placebo; 147 patients
placebo to pregabalin
Weekly MPS at end point
(14 weeks) showed no
signiﬁcant difference
between pregabalin and
placebo. Secondary end
point: mean treatment
difference in DPN-
related sleep
interference, favoured
pregabalin over placebo
(P = 0.0009)
Multi-centre
47 study centres in US
[43], Czech Republic
[3], Italy [1]
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Table 3 continued
Publication(s) Study title NCT ID No. patients randomised Primary outcome
measures/results
Country (no. of study
centres)
Raskin et al.
[122]
A phase 3B multi-centre,
double-blind,
randomised withdrawal
efﬁcacy and safety study
of pregabalin in the
treatment of patients
with inadequately
treated painful diabetic
peripheral neuropathy
NCT0105
7693
665 patients in 6-week
single-blind run-in
period (pregabalin
300 mg/day); 294
patients with[ 30%
pain response were
randomised to receive
pregabalin
(300 mg/day) or
placebo for a further
12 weeks
In single-blind treatment
phase, MPS decreased
numerically. In double-
blind treatment phase,
MPS pregabalin group
decreased from 6.8 at
single-blind baseline to
2.9 (1.7) at double-blind
end point, a change
from single-blind
baseline of - 3.9 (1.9).
MPS placebo group
decreased from 6.7 at
single-blind baseline to
3.2 (1.9), a change from
single-blind phase of
- 3.5 (2.1); least squares
mean difference,
- 0.32), no signiﬁcant
difference
Multi-centre
129 study centres in the
US [113], South
Africa [11], Canada
[5]
Satoh et al.
[123]
Randomised, double-blind,
multi-centre, placebo-
controlled study to
evaluate efﬁcacy and
safety of pregabalin (CI-
1008) in the treatment
for pain associated with
diabetic peripheral
neuropathy
NCT0055
3475
317 patients (placebo or
pregabalin at 300 or
600 mg/day)
Signiﬁcant reductions in
pain with pregabalin at
300 and 600 mg/day vs.
placebo, observed as
early as week 1 and
sustained throughout
study period (- 0.63
and - 0.74,
respectively)
Multi-centre Japanese
population
Gilron et al.
[52]
A randomised, placebo-
controlled trial of the
efﬁcacy and safety of
pregabalin in the
treatment of subjects
with peripheral
neuropathic pain
NCT0021
9544
256 patients in run-in
period; 165 (65%)
had[ 30% pain
improvement, 157 were
randomised to either
pregabalin (n = 80) or
to receive placebo
(n = 77)
At the double-blind end
point, MPS was 2.9
(1.9) in pregabalin
group and 3.5 (1.7) in
placebo group
(P = 0.002)
Multi-centre Canadian
population [25]
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Table 3 continued
Publication(s) Study title NCT ID No. patients randomised Primary outcome
measures/results
Country (no. of study
centres)
Guan et al.
[124]
An 8-week multi-centre,
randomised, double-
blind, placebo-
controlled study to
evaluate the efﬁcacy,
safety and tolerability of
pregabalin (150–600
mg/day) using a ﬂexible
dosing schedule in the
treatment of subjects
with symptoms of
neuropathic pain
NCT0030
1223
Flexible-dose pregabalin
150–600 mg/day.
Randomised in 2:1
ratio. Treatment
pregabalin (n = 206),
placebo (n = 102)
MPS with pregabalin
resulted in signiﬁcant
improvement compared
with placebo, a least
squares mean difference
score of - 0.6
(P = 0.005); 64% and
52% patients treated
with pregabalin and
placebo, respectively,
reported C 30%
improvement in MPS
(P = 0.04)
Multi-centre
Chinese population
Parsons and Li
[125]
A randomised, double-
blind, placebo-
controlled, parallel-
group, multi-centre trial
of pregabalin versus
placebo in the treatment
of neuropathic pain
associated with diabetic
peripheral neuropathy
NCT0014
3156
Data pooled from 11
placebo-controlled trials
to evaluate efﬁcacy
pregabalin ﬂexible or
ﬁxed dose (150, 300 or
600 mg/day)
At baseline, 1816 patients
had moderate pain
(pregabalin, n = 1189)
and 1119 patients had
severe pain (pregabalin,
n = 720). Pregabalin
(300, 600 mg/day)
signiﬁcantly reduced
MPS at end point
compared with placebo
(p\ 0.01). Pregabalin
improved PRSI and
PGIC in moderate and
severe cohorts compared
with placebo
Multi-centre pooled
data analysis
Freeman et al.
[126]
A 14-week, double-blind,
randomised, placebo-
controlled, multi-centre
study to evaluate the
safety and efﬁcacy of
pregabalin (150–600
mg/day) using a ﬂexible
optimal dose schedule in
patients with painful
diabetic peripheral
neuropathy (DPN)
NCT0015
6078
Data pooled from 16
randomised, placebo-
controlled, parallel-
group, double-blind
trials of pregabalin for
treatment of 3053
patients with DPN
At baseline, MPS of C 4,
for 4 or more days prior
to randomisation.
Flexible dose pregabalin
(150–600 mg/day); no
signiﬁcant difference in
MPS compared with
placebo (A0081030).
No signiﬁcant difference
in MPS with pregabalin
(300 or 600 mg/day)
compared with placebo
(A0081071). No
signiﬁcant difference in
MPS with pregabalin
600 mg/day
(1008–040)
Multi-centre pooled
data analysis (19
countries across Asia,
Europe, Latin
America and Middle
East, US)
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Table 3 continued
Publication(s) Study title NCT ID No. patients randomised Primary outcome
measures/results
Country (no. of study
centres)
Freeman et al.
[127]
Meta-analysis: seven RCTs
across a range of
pregabalin doses
n/a 1510 patients in seven
double-blind RCTs:
pregabalin, n = 953;
placebo, n = 557. MPS
baseline was 6.5
MPS and PRSI score
improved associated
with pregabalin 150,
300 and 600 mg/day
administered TID vs.
placebo, P\ 0.007
Multi-centre pooled
data analysis (90%
patients white, 58%
male)
Freynhagen
et al. [128]
Comprehensive drug safety
evaluation of pregabalin
in pDPN**
n/a 7510 patients included:
4884 on pregabalin and
2626 on placebo
31 RCTs of pregabalin in
pDPN
Incidence of adverse
events: dizziness (risk
difference [95% CI]:
17.0 [15.4 to 18.6]),
somnolence (10.8 [9.5
to 12.1]), peripheral
oedema (5.4[4.3 to
6.4]), weight increase
(4.7 [3.9 to 5.5]), dry
mouth (2.9 [2.1 to 3.8]),
constipation (2.3[1.5 to
3.2]), blurred vision (2.2
[1.6 to 2.9]), balance
disorder (2.0 [1.5 to 2.5]
and euphoric mood (1.6
[1.2 to 2.0])
Multi-centre pooled
analysis RCT in Asia,
Australia, Canada,
Europe, Latin
America, the Middle
East, South Africa
and the US
Semel et al.
[129]
Evaluation of safety and
efﬁcacy of pregabalin in
older patients with
neuropathic pain: results
from a pooled analysis
of 11 clinical studies
n/a 2516 patients (white,
n = 2344; male,
n = 1347): pregabalin,
n = 1595
MPS end point
improvement observed
for all pregabalin
dosages
(150–600 mg/day) in
older patients
(age C 65 years old)
(p B 0.0009)
Multi-centre (white
predominant)
Moon et al.
[130]
A 10-week, randomised,
double-blind, placebo-
controlled, multi-centre
study to evaluate the
efﬁcacy and safety of
pregabalin (150–600
mg/day) using a ﬂexible,
optimised dose schedule
in subjects with
peripheral neuropathic
pain
NCT0014
1219
240 patients. Phase III
trial. 2:1 ratio to
pregabalin
(150–600 mg/day) or
placebo. Pregabalin,
n = 162, placebo,
n = 78
MPS signiﬁcantly lower in
pregabalin group than in
placebo; least square
mean difference,
- 0.50; - 1.00 to 0.00;
P = 0.049)
Korean population
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Table 3 continued
Publication(s) Study title NCT ID No. patients randomised Primary outcome
measures/results
Country (no. of study
centres)
Arezzo et al.
[131]
A 13-week, double-blind,
placebo-controlled
phase 4 trial of
pregabalin (CI-1008,
600 mg/day) for relief
of pain in subjects with
painful diabetic
peripheral neuropathy
NCT0015
9679
167 patients (pregabalin,
n = 82, placebo,
n = 85)
MPS lower than placebo
(mean difference
- 1.28; P\ 0.001)
US
23 study centres
Freynhagen
et al. [49]
Efﬁcacy and safety of
pregabalin using an
individual optimal twice
a day (BID) dose
schedule in patients
with chronic
neuropathic pain
n/a 338 patients randomised
in 1:2:2 ratio to placebo,
ﬂexible-dose pregabalin
(150–600 mg/day) or
ﬁxed dose pregabalin
(600 mg/day). PGB
ﬂexible dose, n = 141;
PGB ﬁxed dose,
n = 132; placebo,
n = 65
MPS signiﬁcantly reduced
for both ﬂexible- and
ﬁxed-dose pregabalin
versus placebo
(P = 0.002) and PRSI
signiﬁcantly improved
European
60 study centres across 9
EU countries
Tolle et al.
2012 [132]
A 12-week, randomised,
double-blind, multi-
centre, placebo-
controlled study of
pregabalin twice a day
(BID) for relief of pain
associated with diabetic
peripheral neuropathy
n/a 395 participants MPS improved in
participants receiving
pregabalin 600 mg/day;
46% reported[ 50%
improvement MPS
from baseline vs.
placebo patients
(P = 0.036). NNT was
6.3. Improvement in
EQ-5D utility scores (all
pregabalin doses vs.
placebo. Number
needed to harm
(discontinuation
because of adverse
events) was 10.3 for
pregabalin 600 mg/day
European
58 study centres in
Europe (Germany,
Hungary, Poland and
the UK), Australia
and South Africa
NCT ID clinicaltrials.gov registry number, LOCF last observation carried forward, MPS mean pain score; DPRS = daily pain rating scale, PRSI
pain-related sleep interference, PGIC patient global impression of change, NNT number needed to treat
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stages and at the final end point [52]. This was
found to be greater in the pregabalin cohort
compared with placebo in both pDPN and post-
herpetic neuralgia [52].
In clinical practice, lack of dose titration is
common in primary care resulting in inade-
quate pain relief. Physicians treating patients
with pDPN should escalate pregabalin to the
dose that delivers optimal analgesia and tolera-
ble side effects [53].
Head-to-Head Trials of Comparators,
Combination Therapy and Meta-Analyses
In head-to-head studies of active comparators in
pDPN, Bansal et al. [54] found no difference in
the outcomes between amitriptyline and pre-
gabalin. However, there was a greater propor-
tion of adverse events in the amitriptyline
group, 65% compared with 25% for pregabalin,
and the preferred dose of pregabalin was 150 mg
BID. A further RCT comparing pregabalin,
amitriptyline and duloxetine found no single
treatment was superior [55]. Pregabalin was
found to improve sleep continuity, whereas
duloxetine increased wake and reduced total
sleep time [55]. There were significantly more
adverse events in the pregabalin group. A meta-
analysis by Quilici et al. [56] (funded by Eli
Lilly) determining the comparative efficacy of
duloxetine vs. pregabalin and gabapentin
through an indirect analysis found that all were
superior to placebo for all efficacy parameters,
with some tolerability trade-offs. Indirect com-
parison of duloxetine with pregabalin found no
differences in 24-h average pain score but sig-
nificant differences in patient global impression
outcomes, favouring pregabalin, and in dizzi-
ness, favouring duloxetine [56]. The estimated
NNT for duloxetine was 5 (95% CI: 3–7) [56],
which was comparable to NNTs reported else-
where of 5.2 (95% CI: 3.7–8.5) and 4.1 (95% CI:
2.9–7.2) [8, 57] and to the NNT for pregabalin of
5 (95% CI: 4–8). The NNH for pregabalin was 19
(95% CI: 10–48) compared with duloxetine with
an NNH of 11 (95% CI: 7–23) [56]. In a study
conducted in Spain (and funded by Pfizer) of
pregabalin versus usual care (antidepressants,
opioids, anticonvulsants different from
pregabalin) in the management of community-
treated patients with refractory pDPN, prega-
balin was associated with a non-significant
higher quality-adjusted life-year (QALY) gain in
a 12-week period [58]. In a further study by the
same group, compared with gabapentin, prega-
balin yielded an estimated mean of 8 [standard
error (SE): 0.4] additional days with no or mild
pain, 6 (SE: 0.4) days with C 30% reduction in
pain intensity, 9 (0.5) days with C 50% reduc-
tion in pain intensity and a gain of 0.1186
(0.0002) QALYs for 12 weeks [59]. Although the
average study drug cost was higher for prega-
balin than gabapentin (€214.6 vs. €157.4:
P\ 0.001), there was a lower cost of concomi-
tant analgesic medication (€176.5 vs. €306.7;
P\ 0.001) [59].
The complex nature of pDPN may require
more than one therapy for adequate pain relief,
but there are limited studies of combination
therapies [60]. The COMBO-DN study is the
largest trial to date comparing monotherapy
with a combination duloxetine and pregabalin
in 339 participants [61]. There was no difference
between combination standard-dose and high-
dose monotherapy of either treatment [61]. In a
secondary analysis, duloxetine 60 mg was found
to be superior to pregabalin 300 mg/day in the
initial 8-week run-in phase. A further explora-
tory post hoc analysis of COMBO-DN showed
that high-dose monotherapy was more favour-
able in patients with severe pain, whereas
combination therapy was more beneficial in
patients with moderate and mild pain [62].
Also, patients who received duloxetine
(60 mg/day) as initial therapy had a better
response to combined duloxetine and prega-
balin for evoked or severe tightness and a
greater benefit with high-dose duloxetine
(120 mg/day) for paraesthesia-dysaesthesia
[62, 63]. In another double-blind RCT with a
parallel-group design comparing amitriptyline,
duloxetine and pregabalin there was no signifi-
cant difference in analgesic efficacy [64]. How-
ever, when determining polysomnographic
parameters, pregabalin improved sleep conti-
nuity, whereas duloxetine increased wake and
reduced total sleep time [64]. Despite the puta-
tive negative effects on sleep, duloxetine
enhanced central nervous system arousal and
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performance on sensory motor tasks; however,
there were significantly more adverse events in
the pregabalin group [64].
A study of pregabalin and 5% lidocaine
medicated plaster (n = 229) in post-herpetic
neuralgia or painful DPN [65] showed that
patients who failed to respond to monotherapy
of pregabalin gained additional benefit from the
5% lidocaine patch. This was in contrast to an
RCT of the addition of low-dose 10 mg oxy-
codone or placebo in patients treated with pre-
gabalin where there was no enhancement of the
pain-relieving effects of pregabalin [66].
Anxiety, pDPN and Pregabalin
There is a well-recognised triad of chronic pain,
anxiety/depression and sleep interference,
which impairs the activities of daily living in
pDPN [67]. pDPN has a substantial impact on
quality of life [68, 69], with 50–70% of patients
attending chronic pain clinics reporting sleep
impairment [70–72], [ 20% having major
depression [73–76] and epidemiological data
demonstrating excess anxiety levels compared
with pain-free populations [77].
Pregabalin is approved in the European
Union for use as an anxiolytic agent in the
management of generalised anxiety disorder
(GAD) and is commonly used-off label in the US
[78]. With a mechanism of action distinct from
other anxiolytic agents, it also offers broad-
spectrum treatment for the characteristic psy-
chosomatic symptoms of GAD including
excessive generalised worry, hypervigilance and
persistent nonspecific anxiety [5]. Therefore,
pregabalin is beneficial as a therapy in both
pDPN and anxiety disorders, as a therapy in
itself or as an adjunct.
Numerous studies have demonstrated pre-
gabalin maintains improvements in anxiety
symptoms in the long term and increases the
time to GAD compared with placebo [5]. A ret-
rospective cohort study [79] of three compara-
ble 13–16-week RCTs [42, 80, 81] with their
corresponding 52-week extensions in a Japanese
population evaluated the use of various prega-
balin regimens in pDPN, spinal cord injury (SCI)
and post-herpetic neuralgia. Significant
improvements in pain and sleep interference
were seen after 1 week and subsequently main-
tained across all conditions including pDPN
compared with placebo. At the end of the study,
the least-squares (LS) mean pain scores (LOCF)
were significantly reduced with pregabalin in all
three trials. In the SCI trial, a non-significant
difference in comparison with placebo was
observed for the HADS anxiety and depression
subscale scores in the pregabalin-treated group
[79]. On completion of the studies significantly
more patients treated with pregabalin, experi-
enced a pain reduction C 30% across all RCTs
[42, 80, 81]. An extension of all three trials
additionally demonstrated that reductions in
pain intensity were maintained over a
12-month period [42, 80, 81]. There were also
notable improvements in 6 of the 16 SF-36
subscale scores in the DPN trial; the analgesic
efficacy of pregabalin are similar across multiple
neuropathic pain conditions and also improves
quality-of-life measures and anxiety [79].
Pregabalin in the dose range 200–600 mg/day
(in two or three daily divided doses) significantly
reduces mean pain scores on the Hamilton
Anxiety Scale for GAD and social anxiety disor-
der (SAD) [5, 51]. However, treatment-related
adverse effects occurred in up to 50% of cases, of
which somnolence precipitated study with-
drawal for * 32% patients [51]. An open-label,
non-comparative, flexible-dose study (n = 217)
in pDPN or post-herpetic neuralgia similarly
investigated the correlation of patient and
physician general global impression of change
(patient global impression of change (PGIC) and
clinician global impression of change (CGI))
with changes in pain, sleep and anxiety score as
primary outcomes assessed on visual or numeric
scales [82]. This multi-centre study identified
significant improvements in pain, anxiety and
sleep (- 40%,- 42%,- 43%, respectively) when
treated with pregabalin over 4 weeks from base-
line to the end of the study [82]. The mean dose
was * 300 mg/day but a limitation of these
findings is the variable dosing regimen used [82].
Nonetheless, both pain and anxiety correlated
with PGIC and CIGC and all correlations except
paired CGIC/anxiety were statistically signifi-
cant [82].
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Sleep Interference and Chronic Pain
pDPN is associated with considerable sleep
impairment, which has been highlighted as an
important outcome measure [83, 84]. Sleep
disturbance is associated with lower pain
thresholds [85]. Pain sensitivity follows a diur-
nal pattern in keeping with a circadian vari-
ability with the variability of pain sensitivity
increasing in response to the build-up of sleep
pressure following sleep deprivation or disrup-
tion [86]. This variability has been further
demonstrated in untreated pDPN and post-
herpetic neuralgia in two separate double-blind
randomised controlled crossover trials where a
relative pain intensity increase of 33% between
8 a.m. and 8 p.m. was reported [87–89].
The Locus Coeruleus: A Centre for Pain
and Sleep Mediation
The locus coeruleus (LC) is a cluster of nora-
drenergic neurones in the dorsal pons with
widespread projections throughout the brain
[90]. The activity of the locus coeruleus peaks in
wakefulness, declines during NREM sleep and is
at its lowest during rapid eye movement (REM)
sleep [90]. The LC has a complex role in neu-
ropathic pain modulation as it may facilitate as
well as inhibit pain development and mainte-
nance of allodynia and hyperalgesia after nerve
injury [91]. Studies limited to animal models
have shown increased activity of the LC via
surrogate markers of gene expression, which
was directly proportional to the degree of allo-
dynia [92]. Furthermore, an agonistic and
analgesic effect was demonstrated when sub-
stance P was injected directly into the LC [93].
However, this effect was negated by prior
injection of a neurokinin-1 receptor antagonist
(the functional binding site of substance-P) and
another agent, yohimbine, an alpha-2 adrener-
gic receptor antagonist [94]. Gabapentin
demonstrates an ‘anti-hypersensitivity’ effect
thought to be a direct effect on the LC in male
rats in a peripheral nerve injury model, which
shows increased LC activity [95].
Pregabalin, pDPN and Sleep
Pregabalin has shown considerable efficacy for
improved sleep interference as demonstrated by
an improvement in sleep quality in 77% of
patients [96]. Pregabalin and gabapentin are
effective in treating neuropathic pain and have
a positive effect on co-morbid sleep disturbance
compared with opiates and antidepressants
[97]. Sleep disturbance as well as its severity
correlates with the severity of neuropathic pain
and is a predictor of response to pregabalin in a
post hoc analysis of placebo-controlled trials
[98]. Pregabalin significantly reduced pain
scores and the greatest reduction was seen in
those with the severest indices of sleep distur-
bance at baseline [98].
In a systematic review of nine clinical trials,
pregabalin was found to be an effective and
well-tolerated therapy to reduce pain and pain-
related sleep disturbance in pDPN and post-
herpetic neuralgia [99]. It is important to note,
however, that none of these studies reported
objective sleep measures [99].
Phantom Limb and Pregabalin
Diabetes is the most common cause of non-
traumatic lower limb amputation, with diabetic
foot ulcers preceding[ 80% of amputations in
people with diabetes [100]. Phantom limb pain
(PLP) can affect up to 80% of amputees [101]
and is associated with considerable distress to
patients and their carers. Pain often commences
shortly after surgery once the initial surgical
insult to the residual stump has passed. The
phantom pain is described as shooting, stab-
bing, throbbing and/or burning, which often
disturbs sleep [102]. It is associated with
increased stress, anxiety, depression and
reduced quality of life [103]. Mobilisation can
be delayed whilst pain control is established,
thus reducing the post-operative rehabilitation
phase [104].
There remains a paucity of data in the use of
pregabalin in PLP [105]. Currently, pre-emptive
use of pregabalin for PLP is sporadic within the
UK. Additional evidence is required in the form
of well-designed and adequately powered RCTs
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to ascertain the role of pregabalin in standard of
care of amputees and PLP. Indeed, a systematic
review of original research studies specifically
investigating the pharmacological treatment of
PLP suggested that gabapentin had a higher
level of evidence than pregabalin [105].
Novel Therapies for pDPN
Voltage-sensitive calcium channels contain
subunits alpha-2-delta 1 (a2d-1) and alpha-2-
delta 2 (a2d-2) subunits. a2d-1 interacts with
NMDA receptors and promotes synaptic
expression of a2d-1-NMDA receptor complexes
in neuropathic pain [106]. Gabapentin and
pregabalin reduce neuropathic pain by non-se-
lectively targeting the a2d-1 subunit bound to
NMDA receptors [107], inhibiting release of
neurotransmitters such as glutamate and
reducing hyperexcitability at the spinal cord.
Mirogabalin (DS-5565) (Daiichi-Sankyo, Japan)
has demonstrated higher affinity for the a2d-1
[108]. Vinik et al. (2014) conducted a large
multi-centre, phase 2 RCT incorporating an
active comparator group with dose-ranging
mirogabalin therapy (5, 10, 15, 20, 30 mg/day)
compared with pregabalin and placebo [109].
An early reduction of average daily pain scores,
sustained after 5 weeks of therapy, was reported
with mirogabalin 15, 20 and 30 mg/day relative
to placebo. In comparison, participants on pre-
gabalin 300 mg/day reported no significant dif-
ference in pain reduction compared with
placebo at the end of a 5-week treatment period.
The most common adverse effects were dizzi-
ness (9.4%), somnolence (6.1%) and headache
(6.1%) [109].
Voltage-gated sodium (Na) channels have
emerged as promising therapeutic targets selec-
tively targeting Nav channels. In particular,
Nav1.7 has attracted the most attention as
humans with Nav1.7 gain-of-function muta-
tions suffer severe chronic pain syndromes
[110]. Numerous trials are ongoing for Nav
channel antagonists. There are ongoing studies
by Pfizer (PF-05089771) [111], entering phase II
trials in DPN), Biogen (BIIB074, previously
known as CNV-1014802) [112], Xenon and
Teva (XEN-402 or TV-45070; phase II in DPN)
[113], Sumitomo Dainippon Pharma (DSP-2230;
phase I trial) [114] and AstraZeneca (AZD-3161;
phase II trial, GlaxoSmithKline (GSK-2339345)
phase II trial) [115] and Gilead (GS-6615) [116].
CONCLUSION
pDPN significantly impacts the individual’s
quality of life, posing threats of chronic pain,
sleep and mood disturbance. Management of
the debilitating burden of pDPN thus requires
symptomatic relief via well-researched phar-
macotherapy such as pregabalin. Recom-
mended as first line in the majority of
guidelines, pregabalin is established as an
effective and relatively well-tolerated agent,
most useful in alleviating subjective sleep and
mood disturbance. Pregabalin has good effi-
cacy for treating pDPN and an adequate safety
profile. Typically reported adverse effects of
dizziness and somnolence prevent up-titration
to the maximum of 600 mg/day. However,
several randomised-controlled trials have
demonstrated symptomatic improvement in
pain and sleep disturbance being achieved at
lower doses (300 mg/day). Despite numerous
large multi-centre RCTs comparing pregabalin
with placebo, the average follow-up duration is
relatively short, averaging at 6 weeks up to the
longest trial duration of 14 weeks. Longer fol-
low-up duration would be necessary to further
evaluate and recognise the potential for sus-
tained benefits and tolerability, although this
should not negatively impact its use as this is
on par with other trials for treatments of
pDPN.
ACKNOWLEDGEMENTS
Funding. No funding or sponsorship was
received for this study or publication of this
article.
Diabetes Ther (2019) 10:35–56 49
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole and have given their
approval for this version to be published.
Disclosures. Uazman Alam has received
honoraria for educational meetings from Pfizer
and Eli Lilly and is currently a local investigator
for BIIB074 (Biogen: NCT03339336). Rayaz A.
Malik has received honoraria for educational
meetings from Pfizer and Eli Lilly. Shazli Azmi
has received honoraria for educational meetings
from Eli Lilly. Kariem T. ElHadd, Andrew Nel-
son, Adam Chapman, Frank L. Bowling,
Anughara Perumbalath, Jonathan Lim and
Andrew Marshall have nothing to disclose.
Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
Data Availability. No new data were gen-
erated during this narrative review of published
studies.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any non-
commercial use, distribution, and reproduction
in any medium, provided you give appropriate
credit to the original author(s) and the source,
provide a link to the Creative Commons license,
and indicate if changes were made.
REFERENCES
1. Andruszkiewicz R, Silverman RB. 4-Amino-3-
alkylbutanoic acids as substrates for gamma-
aminobutyric acid aminotransferase. J Biol Chem.
1990;265(36):22288–91.
2. Pritchard N, Edwards K, Russell AW, Perkins BA,
Malik RA, Efron N. Corneal confocal microscopy
predicts 4-year incident peripheral neuropathy in
type 1 diabetes. Diabetes care. 2015:dc142114.
3. Toth C. Pregabalin: latest safety evidence and clin-
ical implications for the management of neuro-
pathic pain. Ther Adv Drug Saf. 2014;5(1):38–56.
4. D’Arcy Y, McCarberg B, Parsons B, Behar R, Thorpe
A, Alexander A. Pregabalin for the treatment of
neuropathic pain: a narrative review for primary
care providers. Curr Med Res Opin.
2017;33(8):1353–9.
5. Frampton JE. Pregabalin: a review of its use in adults
with generalized anxiety disorder. CNS Drugs.
2014;28(9):835–54.
6. Tavakoli M, Mitu-Pretorian M, Petropoulos IN,
Fadavi H, Asghar O, Alam U, et al. Corneal confocal
microscopy detects early nerve regeneration in
diabetic neuropathy after simultaneous pancreas
and kidney transplantation. Diabetes.
2012:DB_120574.
7. Handelsman Y, Bloomgarden ZT, Grunberger G,
Umpierrez G, Zimmerman RS, Bailey TS, et al.
American Association of Clinical Endocrinologists
and American College of Endocrinology-Clinical
Practice Guidelines for Developing a Diabetes Mel-
litus Comprehensive Care Plan–2015—executive
summary. Endocr Pract. 2015;21(4):413–37.
8. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P,
Jensen TS, et al. EFNS guidelines on the pharmaco-
logical treatment of neuropathic pain: 2010 revi-
sion. Eur J Neurol. 2010;17(9):1113-e88.
9. Bril V, England J, Franklin GM, Backonja M, Cohen
J, Del Toro D, et al. Evidence-based guideline:
treatment of painful diabetic neuropathy: report of
the American Academy of Neurology, the American
Association of Neuromuscular and Electrodiagnos-
tic Medicine, and the American Academy of Physi-
cal Medicine and Rehabilitation. Neurology.
2011;76(20):1758–65.
10. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Free-
man R, Malik RA, et al. Diabetic neuropathy: a
position statement by the American Diabetes Asso-
ciation. Diabetes Care. 2017;40(1):136–54.
11. NICE. Neuropathic pain in adults: pharmacological
management in non-specialist settings. NICE. 2017.
12. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N,
Duffy S, Clusmann H, et al. Inhibition of neuronal
Ca(2 ?) influx by gabapentin and pregabalin in the
human neocortex. Neuropharmacology.
2002;42(2):229–36.
13. Hutson SM, Berkich D, Drown P, Xu B, Aschner M,
LaNoue KF. Role of branched-chain
50 Diabetes Ther (2019) 10:35–56
aminotransferase isoenzymes and gabapentin in
neurotransmitter metabolism. J Neurochem.
1998;71(2):863–74.
14. Micheva KD, Taylor CP, Smith SJ. Pregabalin redu-
ces the release of synaptic vesicles from cultured
hippocampal neurons. Mol Pharmacol.
2006;70(2):467–76.
15. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay
HJ. Pregabalin for acute and chronic pain in adults.
Cochrane Database Syst Rev. 2009;3:Cd007076.
16. Lauria-Horner BA, Pohl RB. Pregabalin: a new anx-
iolytic. Expert Opin Investig Drugs.
2003;12(4):663–72.
17. Azmi S, Ferdousi M, Petropoulos IN, Ponirakis G,
Fadavi H, Tavakoli M, et al. Corneal confocal
microscopy shows an improvement in small-fiber
neuropathy in subjects with type 1 diabetes on
continuous subcutaneous insulin infusion com-
pared with multiple daily injection. Diabetes Care.
2015;38(1):e3–4.
18. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ,
Cook JA, Bockbrader HN. Pharmacokinetics of pre-
gabalin in subjects with various degrees of renal
function. J Clin Pharmacol. 2003;43(3):277–83.
19. Bockbrader HN, Wesche D, Miller R, Chapel S,
Janiczek N, Burger P. A comparison of the phar-
macokinetics and pharmacodynamics of pregabalin
and gabapentin. Clin Pharmacokinet.
2010;49(10):661–9.
20. Schifano F. Misuse and abuse of pregabalin and
gabapentin: cause for concern? CNS Drugs.
2014;28(6):491–6.
21. Statistics OfN. Deaths related to drug poisoning in
England and Wales: 2016 registrations 2017.
https://www.ons.gov.uk/peoplepopulationandcom
munity/birthsdeathsandmarriages/deaths/bulletins/
deathsrelatedtodrugpoisoninginenglandandwales/
2016registrations—people-aged-40-to-49-years-have-
the-highest-rate-of-drug-misuse-deaths.
22. Iacobucci G. UK government to reclassify prega-
balin and gabapentin after rise in deaths. BMJ.
2017;358.
23. Stannard C, Brew I, Browne E, Brinksman S, Collett
B, Gilvarry E, et al. Advice for prescribers on the risk
of the misuse of pregabalin and gabapentin. Public
Health England and NHS England; 2014:pp 1–9.
24. International Diabetes Federation. IDF Diabetes
Atlas. 8th ed. Brussels: International Diabetes Fed-
eration; 2017.
25. Gordois A, Scuffham P, Shearer A, Oglesby A,
Tobian JA. The health care costs of diabetic
peripheral neuropathy in the US. Diabetes Care.
2003;26(6):1790–5.
26. Van Acker K, Bouhassira D, De Bacquer D, Weiss S,
Matthys K, Raemen H, et al. Prevalence and impact
on quality of life of peripheral neuropathy with or
without neuropathic pain in type 1 and type 2
diabetic patients attending hospital outpatients
clinics. Diabetes Metab. 2009;35(3):206–13.
27. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL,
Freeman R, et al. Diabetic neuropathies a statement
by the American Diabetes Association. Diabetes
Care. 2005;28(4):956–62.
28. Tolle T, Freynhagen R, Versavel M, Trostmann U,
Young JP Jr. Pregabalin for relief of neuropathic
pain associated with diabetic neuropathy: a ran-
domized, double-blind study. Eur J Pain.
2008;12(2):203–13.
29. Food Drug Administration Centre for Drugs Evalu-
ation Research. Highlights of Prescribing Informa-
tion (LYRICA) Pregabalin. FDA Maryland; 2012.
30. MacDermott AB. Glutamate and GABA: a painful
combination. Neuron. 2001;32(3):376–8.
31. Bardoni R, Takazawa T, Tong CK, Choudhury P,
Scherrer G, Macdermott AB. Pre- and postsynaptic
inhibitory control in the spinal cord dorsal horn.
Ann N Y Acad Sci. 2013;1279:90–6.
32. Zeilhofer HU, Wildner H, Yevenes GE. Fast synaptic
inhibition in spinal sensory processing and pain
control. Physiol Rev. 2012;92(1):193–235.
33. Coull JA, Boudreau D, Bachand K, Prescott SA, Nault
F, Sik A, et al. Trans-synaptic shift in anion gradient
in spinal lamina I neurons as a mechanism of neu-
ropathic pain. Nature. 2003;424(6951):938–42.
34. Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F,
et al. Pregabalin is a potent and selective ligand for
alpha(2)delta-1 and alpha(2)delta-2 calcium chan-
nel subunits. Eur J Pharmacol.
2011;667(1–3):80–90.
35. Patel R, Bauer CS, Nieto-Rostro M, Margas W, Ferron
L, Chaggar K, et al. alpha2delta-1 gene deletion
affects somatosensory neuron function and delays
mechanical hypersensitivity in response to periph-
eral nerve damage. J Neurosci.
2013;33(42):16412–26.
36. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ,
et al. Identification of the alpha2-delta-1 subunit of
voltage-dependent calcium channels as a molecular
target for pain mediating the analgesic actions of
Diabetes Ther (2019) 10:35–56 51
pregabalin. Proc Natl Acad Sci USA.
2006;103(46):17537–42.
37. Ben-Menachem E. Pregabalin pharmacology and its
relevance to clinical practice. Epilepsia.
2004;45(Suppl 6):13–8.
38. Hong T, Han S, Lee J, Jeon S, Yim DS. Comparison
of oral absorption models for pregabalin: usefulness
of transit compartment model. Drug Des, Dev Ther.
2016;10:3995–4003.
39. Bockbrader HN, Radulovic LL, Posvar EL, Strand JC,
Alvey CW, Busch JA, et al. Clinical pharmacoki-
netics of pregabalin in healthy volunteers. J Clin
Pharmacol. 2010;50(8):941–50.
40. Bockbrader HN, Burger P, Knapp L, Corrigan BW.
Population pharmacokinetics of pregabalin in
healthy subjects and patients with chronic pain or
partial seizures. Epilepsia. 2011;52(2):248–57.
41. Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A,
Yoshiyama T. Efficacy and safety evaluation of
pregabalin treatment over 52 weeks in patients with
diabetic neuropathic pain extended after a double-
blind placebo-controlled trial. J Diabetes Investig.
2011;2(6):457–63.
42. Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A,
Yoshiyama T, et al. Efficacy and safety of pregabalin
for treating neuropathic pain associated with dia-
betic peripheral neuropathy: a 14 week, random-
ized, double-blind, placebo-controlled trial.
Diabetic Med J Br Diabetic Assoc.
2011;28(1):109–16.
43. Zaccara G, Gangemi P, Perucca P, Specchio L. The
adverse event profile of pregabalin: a systematic
review and meta-analysis of randomized controlled
trials. Epilepsia. 2011;52(4):826–36.
44. Parsons B, Emir B. Glycemic and serum lipid control
in patients with painful diabetic peripheral neu-
ropathy treated with pregabalin. J Diabetes Com-
plicat. 2017;31(2):489–93.
45. Verma V, Singh N, Singh Jaggi A. Pregabalin in
neuropathic pain: evidences and possible mecha-
nisms. Curr Neuropharmacol. 2014;12(1):44–56.
46. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U.
Pregabalin for the treatment of painful diabetic
peripheral neuropathy: a double-blind, placebo-
controlled trial. Pain. 2004;110(3):628–38.
47. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pre-
gabalin relieves symptoms of painful diabetic neu-
ropathy: a randomized controlled trial. Neurology.
2004;63(11):2104–10.
48. Richter RW, Portenoy R, Sharma U, Lamoreaux L,
Bockbrader H, Knapp LE. Relief of painful diabetic
peripheral neuropathy with pregabalin: a random-
ized, placebo-controlled trial. J Pain.
2005;6(4):253–60.
49. Freynhagen R, Strojek K, Griesing T, Whalen E,
Balkenohl M. Efficacy of pregabalin in neuropathic
pain evaluated in a 12-week, randomised, double-
blind, multicentre, placebo-controlled trial of flex-
ible- and fixed-dose regimens. Pain.
2005;115(3):254–63.
50. Zhang SS, Wu Z, Zhang LC, Zhang Z, Chen RP,
Huang YH, et al. Efficacy and safety of pregabalin
for treating painful diabetic peripheral neuropathy:
a meta-analysis. Acta Anaesthesiol Scand.
2015;59(2):147–59.
51. Tassone DM, Boyce E, Guyer J, Nuzum D. Prega-
balin: a novel gamma-aminobutyric acid analogue
in the treatment of neuropathic pain, partial-onset
seizures, and anxiety disorders. Clin Ther.
2007;29(1):26–48.
52. Gilron I, Wajsbrot D, Therrien F, Lemay J. Prega-
balin for peripheral neuropathic pain: a multicen-
ter, enriched enrollment randomized withdrawal
placebo-controlled trial. Clin J Pain.
2011;27(3):185–93.
53. Serpell M, Latymer M, Almas M, Ortiz M, Parsons B,
Prieto R. Neuropathic pain responds better to
increased doses of pregabalin: an in-depth analysis
of flexible-dose clinical trials. J Pain Res.
2017;10:1769–76.
54. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta
P. Amitriptyline vs. pregabalin in painful diabetic
neuropathy: a randomized double blind clinical
trial. Diabet Med. 2009;26(10):1019–26.
55. Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S,
Coppini DV, et al. Randomized, placebo-controlled
comparison of amitriptyline, duloxetine, and pre-
gabalin in patients with chronic diabetic peripheral
neuropathic pain: impact on pain, polysomno-
graphic sleep, daytime functioning, and quality of
life. Diabetes Care. 2012;35(12):2451–8.
56. Quilici S, Chancellor J, Lo¨thgren M, Simon D, Said
G, Le TK, et al. Meta-analysis of duloxetine vs pre-
gabalin and gabapentin in the treatment of diabetic
peripheral neuropathic pain. BMC Neurol.
2009;9(1):6.
57. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sin-
drup SH. Algorithm for neuropathic pain treatment:
an evidence based proposal. Pain.
2005;118(3):289–305.
52 Diabetes Ther (2019) 10:35–56
58. de Salas-Cansado M, Pe´rez C, Saldan˜a MT, Navarro
A, Gonza´lez-Go´mez FJ, Ruiz L, et al. An economic
evaluation of pregabalin versus usual care in the
management of community-treated patients with
refractory painful diabetic peripheral neuropathy in
primary care settings. Primary Care Diabetes.
2012;6(4):303–12.
59. Rodrı´guez MJ, Dı´az S, Vera-Llonch M, Dukes E, Rejas
J. Cost-effectiveness analysis of pregabalin versus
gabapentin in the management of neuropathic pain
due to diabetic polyneuropathy or post-herpetic
neuralgia. Curr Med Res Opin.
2007;23(10):2585–96.
60. Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M,
Cuthbertson DJ, et al. Diabetic peripheral neu-
ropathy: epidemiology, diagnosis, and pharma-
cotherapy. Clin Ther. 2018;40(6):828–49.
61. Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tolle T,
Bouhassira D, et al. Duloxetine and pregabalin:
high-dose monotherapy or their combination? The
‘‘COMBO-DN study’’—a multinational, random-
ized, double-blind, parallel-group study in patients
with diabetic peripheral neuropathic pain. Pain.
2013;154(12):2616–25.
62. Bouhassira D, Wilhelm S, Schacht A, Perrot S, Kosek
E, Cruccu G, et al. Neuropathic pain phenotyping as
a predictor of treatment response in painful diabetic
neuropathy: data from the randomized, double-
blind, COMBO-DN study. Pain.
2014;155(10):2171–9.
63. Rolim LC, Koga da Silva EM, De Sa´ JR, Dib SA. A
systematic review of treatment of painful diabetic
neuropathy by pain phenotype versus treatment
based on medical comorbidities. Front Neurol.
2017;8:285.
64. Boyle J, Eriksson MEV, Gribble L, Gouni R, Johnsen
S, Coppini DV, et al. Randomized, placebo-con-
trolled comparison of amitriptyline, duloxetine,
and pregabalin in patients with chronic diabetic
peripheral neuropathic pain. Impact on pain,
polysomnographic sleep, daytime functioning, and
quality of life. 2012.
65. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald
I, Serpell M. Efficacy and safety of combination
therapy with 5% lidocaine medicated plaster and
pregabalin in post-herpetic neuralgia and diabetic
polyneuropathy. Curr Med Res Opin.
2009;25(7):1677–87.
66. Zin CS, Nissen LM, O’Callaghan JP, Duffull SB,
Smith MT, Moore BJ. A randomized, controlled trial
of oxycodone versus placebo in patients with pos-
therpetic neuralgia and painful diabetic neuropathy
treated with pregabalin. J Pain. 2010;11(5):462–71.
67. Tarride JE, Gordon A, Vera-Llonch M, Dukes E,
Rousseau C. Cost-effectiveness of pregabalin for the
management of neuropathic pain associated with
diabetic peripheral neuropathy and postherpetic
neuralgia: a Canadian perspective. Clin Ther.
2006;28(11):1922–34.
68. Galer BS, Gianas A, Jensen MP. Painful diabetic
polyneuropathy: epidemiology, pain description,
and quality of life. Diabetes Res Clin Pract.
2000;47(2):123–8.
69. Benbow SJ, Wallymahmed ME, Macfarlane IA. Dia-
betic peripheral neuropathy and quality of life. QJM
Mon J Assoc Phys. 1998;91(11):733–7.
70. Atkinson JH, Ancoli-Israel S, Slater MA, Garfin SR,
Dillin JC. Subjective sleep disturbance in chronic
back pain. Clin J Pain. 1988;4(4):225–32.
71. Morin CM, Gibson D, Wade J. Self-reported sleep
and mood disturbance in chronic pain patients.
Clin J Pain. 1998;14(4):311–4.
72. Pilowsky I, Crettenden I, Townley M. Sleep distur-
bance in pain clinic patients. Pain.
1985;23(1):27–33.
73. Banks SM, Kerns RD. Explaining high rates of
depression in chronic pain: a diathesis-stress
framework. Psychol Bull. 1996;119(1):95–110.
74. Dworkin RH, Gitlin MJ. Clinical aspects of depres-
sion in chronic pain patients. Clin J Pain.
1991;7(2):79–94.
75. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS.
Chronic pain-associated depression: antecedent or
consequence of chronic pain? A review. Clin J Pain.
1997;13(2):116–37.
76. Sullivan MJL, Reesor K, Mikail S, Fisher R. The
treatment of depression in chronic low back pain:
review and recommendations. Pain.
1992;50(1):5–13.
77. McWilliams LA, Cox BJ, Enns MW. Mood and
anxiety disorders associated with chronic pain: an
examination in a nationally representative sample.
Pain. 2003;106(1–2):127–33.
78. Greenblatt HK, Greenblatt DJ. Gabapentin and
pregabalin for the treatment of anxiety disorders.
Clin Pharmacol Drug Dev. 2018;7(3):228–32.
79. Ogawa S, Arakawa A, Hayakawa K, Yoshiyama T.
Pregabalin for neuropathic pain: why benefits could
be expected for multiple pain conditions. Clin Drug
Investig. 2016;36(11):877–88.
80. Ogawa S, Suzuki M, Arakawa A, Araki S, Yoshiyama
T. Evaluation of the efficacy and safety of pregabalin
Diabetes Ther (2019) 10:35–56 53
in the treatment of postherpetic neuralgia: a ran-
domized, double-blind, multicenter, placebo-con-
trolled study. J Jpn Soc Pain Clin. 2010;17:141–52.
81. Cardenas DD, Nieshoff EC, Suda K, Goto S, Sanin L,
Kaneko T, et al. A randomized trial of pregabalin in
patients with neuropathic pain due to spinal cord
injury. Neurology. 2013;80(6):533–9.
82. Baron R, Brunnmuller U, Brasser M, MayM, Binder A.
Efficacy and safety of pregabalin in patients with dia-
betic peripheral neuropathyor postherpetic neuralgia:
open-label, non-comparative, flexible-dose study. Eur
J Pain (London, England). 2008;12(7):850–8.
83. Hwang S, van Nooten F, Wells T, Ryan A, Crawford
B, Evans C, et al. Neuropathic pain: a patient-cen-
tred approach to measuring outcomes. Health
expectations: an international journal of public
participation in health care and health policy. 2018.
84. Zelman DC, Brandenburg NA, Gore M. Sleep
impairment in patients with painful diabetic
peripheral neuropathy. Clin J Pain.
2006;22(8):681–5.
85. Sivertsen B, Lallukka T, Petrie KJ, Steingrimsdottir
OA, Stubhaug A, Nielsen CS. Sleep and pain sensi-
tivity in adults. Pain. 2015;156(8):1433–9.
86. Hagenauer MH, Crodelle JA, Piltz SH, Toporikova N,
Ferguson P, Booth V. The Modulation of pain by
circadian and sleep-dependent processes: a review
of the experimental evidence. bioRxiv. 2017.
87. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF,
Houlden RL. Morphine, gabapentin, or their com-
bination for neuropathic. Pain.
2005;352(13):1324–34.
88. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC,
Houlden RL. Nortriptyline and gabapentin, alone
and in combination for neuropathic pain: a double-
blind, randomised controlled crossover trial. Lan-
cet. 2009;374(9697):1252–61.
89. Gilron I, Bailey JM, Vandenkerkhof EG. Chronobi-
ological characteristics of neuropathic pain: clinical
predictors of diurnal pain rhythmicity. Clin J Pain.
2013;29(9):755–9.
90. Horner RL, Peever JH. Brain circuitry controlling
sleep and wakefulness. Continuum (Minneap
Minn). 2017;23(4, Sleep Neurology):955–72.
91. Taylor BK, Westlund KN. The noradrenergic locus
coeruleus as a chronic pain generator. J Neurosci
Res. 2017;95(6):1336–46.
92. Brightwell JJ, Taylor BK. Noradrenergic neurons in
the locus coeruleus contribute to neuropathic pain.
Neuroscience. 2009;160(1):174–85.
93. Garcia-Recio S, Gasco´n P. Biological and pharma-
cological aspects of the NK1-receptor. Biomed Res
Int. 2015;2015:495704.
94. Muto Y, Sakai A, Sakamoto A, Suzuki H. Activation
of NK(1) receptors in the locus coeruleus induces
analgesia through noradrenergic-mediated
descending inhibition in a rat model of neuropathic
pain. Br J Pharmacol. 2012;166(3):1047–57.
95. Hayashida K, Obata H, Nakajima K, Eisenach JC.
Gabapentin acts within the locus coeruleus to alle-
viate neuropathic pain. Anesthesiology.
2008;109(6):1077–84.
96. Lampl C, Schweiger C, Haider B, Lechner A. Prega-
balin as mono- or add-on therapy for patients with
refractory chronic neuropathic pain: a post-mar-
keting prescription-event monitoring study. J Neu-
rol. 2010;257(8):1265–73.
97. Ferini-Strambi L. Neuropathic pain and sleep: a
review. Pain Ther. 2017;6(Suppl 1):19–23.
98. Vinik A, Emir B, Parsons B, Cheung R. Prediction of
pregabalin-mediated pain response by severity of
sleep disturbance in patients with painful diabetic
neuropathy and post-herpetic neuralgia. Pain Med.
2014;15(4):661–70.
99. Roth T, van Seventer R, Murphy TK. The effect of
pregabalin on pain-related sleep interference in
diabetic peripheral neuropathy or postherpetic
neuralgia: a review of nine clinical trials. Curr Med
Res Opin. 2010;26(10):2411–9.
100. Coppini D. New NICE guidelines on diabetic foot
disease prevention and management. Pract Dia-
betes. 2015;32(8):283.
101. Richardson C, Glenn S, Nurmikko T, Horgan M.
Incidence of phantom phenomena including
phantom limb pain 6 months after major lower
limb amputation in patients with peripheral vas-
cular disease. Clin J Pain. 2006;22(4):353–8.
102. Mortimer CM, Steedman WM, McMillan IR, Martin
DJ, Ravey J. Patient information on phantom limb
pain: a focus group study of patient experiences,
perceptions and opinions. Health Educ Res.
2002;17(3):291–304.
103. van der Schans CP, Geertzen JH, Schoppen T,
Dijkstra PU. Phantom pain and health-related
quality of life in lower limb amputees. J Pain
Symptom Manage. 2002;24(4):429–36.
104. Vanross ER, Johnson S, Abbott CA. Effects of early
mobilization on unhealed dysvascular transtibial
amputation stumps: a clinical trial. Arch Phys Med
Rehabil. 2009;90(4):610–7.
54 Diabetes Ther (2019) 10:35–56
105. McCormick Z, Chang-Chien G, Marshall B, Huang
M, Harden RN. Phantom limb pain: a systematic
neuroanatomical-based review of pharmacologic
treatment. Pain Medicine. 2014;15(2):292–305.
106. Chen J, Li L, Chen SR, Chen H, Xie JD, Sirrieh RE,
et al. The alpha2delta-1-NMDA receptor complex is
critically involved in neuropathic pain develop-
ment and gabapentin therapeutic actions. Cell Rep.
2018;22(9):2307–21.
107. Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-
Minh A, Ferron L, Douglas L, et al. The increased
trafficking of the calcium channel subunit alpha2-
delta-1 to presynaptic terminals in neuropathic
pain is inhibited by the alpha2delta ligand prega-
balin. J Neurosci. 2009;29(13):4076–88.
108. Daiichi-Sankyo. Mirogabalin 2018. https://www.
daiichisankyo.com/media_investors/media_relatio
ns/press_releases/detail/006800.html.
109. Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C,
Merante D. Efficacy and safety of mirogabalin (DS-
5565) for the treatment of diabetic peripheral neu-
ropathic pain: a randomized, double-blind, placebo-
and active comparator-controlled, adaptive proof-
of-concept phase 2 study. Diabetes Care.
2014;37(12):3253–61.
110. Fischer TZ, Waxman SG. Familial pain syndromes
from mutations of the NaV1.7 sodium channel.
Ann N Y Acad Sci. 2010;1184:196–207.
111. A Clinical Trial To Evaluate PF-05089771 on its own
and as an Add-on Therapy to Pregabalin (Lyrica) for
the Treatment of Pain due to Diabetic Peripheral
Neuropathy (DPN). 2014 [cited 2018 June 28].
http://clinicaltrials.gov/ct2/show/NCT02215252?
term=PF-05089771&rank=8.
112. Convergence Pharmaceuticals. Convergence Phar-
maceuticals’ Novel Nav1.7 Selective Sodium Chan-
nel Blocker CNV1014802 Demonstrates Proof of
Concept in Second Neuropathic Pain Study in
Lumbosacral Radiculopathy 2014 [cited 2018 June
28]. http://www.convergencepharma.com/userfiles/
file/140923_LSR_FINAL.pdf.
113. Winters CS, Yang M, Chen H. Pharmaceutical
compositions of spiro-oxindole compound for
topical administration and their use as therapeutic
agents. PCT Int Apple WO2011106729. 2011.
114. Sumitomo Dainippon Pharma Co Ltd. Profile of
Major Products under Development. http://www.
ds-pharma.com/rd/clinical/pipeline_profile.html.
115. Kwong K, Webb EF, Hunsberger GE, et al. Pharma-
cological characterisation of GSK2339345, a novel
voltage-gated sodium channel blocker for the
symptomatic relief of cough. Am J Resp Grit Care
Med. 2013;187:A4936.
116. ClinicalTrials.gov; U.S. National Institutes of
Health: GS-6615 2015. https://clinicaltrials.gov/ct2/
results?term=GS6615&Search=Search.
117. Specialist Pharmacy Service NHS. Mirogabalin 2017.
https://www.sps.nhs.uk/medicines/mirogabalin/.
118. Kato M, Tajima N, Shimizu T, Sugihara M, Furihata
K, Harada K, et al. Pharmacokinetics and safety of a
single oral dose of mirogabalin in Japanese subjects
with varying degrees of renal impairment. J Clin
Pharmacol. 2018;58(1):57–63.
119. Mu Y, Liu X, Li Q, Chen K, Liu Y, Lv X, et al. Efficacy
and safety of pregabalin for painful diabetic
peripheral neuropathy in a population of Chinese
patients: a randomized placebo-controlled trial.
J Diabetes. 2018;10(3):256–65.
120. Huffman C, Stacey BR, Tuchman M, Burbridge C, Li
C, Parsons B, et al. Efficacy and safety of pregabalin
in the treatment of patients with painful diabetic
peripheral neuropathy and pain on walking. Clin J
Pain. 2015;31(11):946–58.
121. Raskin P, Huffman C, Yurkewicz L, Pauer L, Scavone
JM, Yang R, et al. Pregabalin in patients with painful
diabetic peripheral neuropathy using an NSAID for
other pain conditions: a double-blind crossover
study. Clin J Pain. 2016;32(3):203–10.
122. Raskin P, Huffman C, Toth C, Asmus MJ, Messig M,
Sanchez RJ, et al. Pregabalin in patients with inad-
equately treated painful diabetic peripheral neu-
ropathy: a randomized withdrawal trial. Clin J Pain.
2014;30(5):379–90.
123. Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A,
Yoshiyama T, et al. Efficacy and safety of pregabalin
for treating neuropathic pain associated with dia-
betic peripheral neuropathy: a 14 week, random-
ized, double-blind, placebo-controlled trial. Diabet
Med. 2010;28(1):109–16.
124. Guan Y, Ding X, Cheng Y, Fan D, Tan L, Wang Y,
et al. Efficacy of pregabalin for peripheral neuro-
pathic pain: results of an 8-week, flexible-dose,
double-blind, placebo-controlled study conducted
in China. Clin Ther. 2011;33(2):159–66.
125. Parsons B, Li C. The efficacy of pregabalin in
patients with moderate and severe pain due to
diabetic peripheral neuropathy. Curr Med Res Opin.
2016;32(5):929–37.
126. Freeman R, Emir B, Parsons B. Predictors of placebo
response in peripheral neuropathic pain: insights
from pregabalin clinical trials. J Pain Res.
2015;8:257–68.
Diabetes Ther (2019) 10:35–56 55
127. Freeman R, Durso-Decruz E, Emir B. Efficacy,
safety, and tolerability of pregabalin treatment for
painful diabetic peripheral neuropathy: findings
from seven randomized, controlled trials across a
range of doses. Diabetes Care. 2008;31(7):
1448–54.
128. Freynhagen R, Serpell M, Emir B, Whalen E, Parsons
B, Clair A, et al. A comprehensive drug safety eval-
uation of pregabalin in peripheral neuropathic
pain. Pain Pract. 2015;15(1):47–57.
129. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B.
Evaluation of the safety and efficacy of pregabalin
in older patients with neuropathic pain: results
from a pooled analysis of 11 clinical studies. BMC
Family Practice. 2010;11:85.
130. Moon DE, Lee DI, Lee SC, Song SO, Yoon DM, Yoon
MH, et al. Efficacy and tolerability of pregabalin using
a flexible, optimized dose schedule in Korean patients
with peripheral neuropathic pain: a 10-week, ran-
domized, double-blind, placebo-controlled, multi-
center study. Clin Ther. 2010;32(14):2370–85.
131. Arezzo JC, Rosenstock J, LaMoreaux L, Pauer L.
Efficacy and safety of pregabalin 600 mg/d for
treating painful diabetic peripheral neuropathy: a
double-blind placebo-controlled trial. BMC Neurol.
2008;8:33.
132. To¨lle T, Freynhagen R, Versavel M, Trostmann U,
Young JP. Pregabalin for relief of neuropathic pain
associated with diabetic neuropathy: a randomized,
double-blind study. Eur J Pain. 2012;12(2):203–13.
56 Diabetes Ther (2019) 10:35–56
